Windlas Biotech Limited — PPTs, 06-11-2025: Investor Presentation

Windlas Biotech delivered its 11th consecutive quarter of record revenue at Rs 222 Cr in Q2 FY26, with H1 FY26 revenue hitting a new high of Rs 432 Cr, both up 19% YoY. Generic Formulations CDMO (74% revenue, +18% YoY H1), Trade Generics (+25% YoY H1), and Exports (+23% YoY H1) drove this growth. H1 FY26 EBITDA rose 25% YoY to Rs 55 Cr, and PAT increased 22% YoY to Rs 35 Cr, with EPS at Rs 16.91 (+21% YoY).

The company is strategically focused on R&D-led development for complex generics and novel dosage forms. Recent developments include the Plant-2 extension becoming operational, the Injectables facility ramping up commercial supplies, and the Plant-6 expansion progressing well for commissioning in FY26. Windlas also generated Rs 56 Cr in cash from operations and maintains strong liquidity of Rs 237 Cr. Management emphasizes strengthening core capabilities, enhancing operational efficiency, and expanding capabilities to drive sustained shareholder value.